Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
Public ClinicalTrials.gov record NCT01950819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
Study identification
- NCT ID
- NCT01950819
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 2,037 participants
Conditions and interventions
Conditions
Interventions
- Induction therapy Biological
- Corticosteroids Drug
- EVR+rCNI Drug
- MPA+sCNI Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2013 (Actual)
- Primary completion
- Feb 1, 2017 (Actual)
- Completion
- Jan 17, 2018 (Actual)
- Last update posted
- Jan 30, 2019
2013 – 2018
United States locations
- U.S. sites
- 40
- U.S. states
- 21
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35233 | — |
| Novartis Investigative Site | Loma Linda | California | 92354 | — |
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | Los Angeles | California | 90048 | — |
| Novartis Investigative Site | Sacramento | California | 95817-1460 | — |
| Novartis Investigative Site | San Diego | California | 92123 | — |
| Novartis Investigative Site | San Francisco | California | 94115 | — |
| Novartis Investigative Site | San Francisco | California | 94143-0116 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Denver | Colorado | 80210 | — |
| Novartis Investigative Site | Chicago | Illinois | 60612 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21201 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02215 | — |
| Novartis Investigative Site | Burlington | Massachusetts | 01805 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109-0331 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Livingston | New Jersey | 07039 | — |
| Novartis Investigative Site | Buffalo | New York | 14215 | — |
| Novartis Investigative Site | The Bronx | New York | 10467 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Novartis Investigative Site | Durham | North Carolina | 27710 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44106-5048 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Columbus | Ohio | 43210 | — |
| Novartis Investigative Site | Harrisburg | Pennsylvania | 17105-8700 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02903 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29425 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37212-3139 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Houston | Texas | 77030-2400 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Charlottesville | Virginia | 22908 | — |
| Novartis Investigative Site | Seattle | Washington | 98195 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53705 | — |
| Novartis Investigative Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01950819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2019 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01950819 live on ClinicalTrials.gov.